Drug manufacturer Cadila Healthcare has said that its product — Lyssavac N (the purified duck embryo rabies vaccine) has been approved by the World Health Organisation (WHO) for purchase by various agencies of United Nations.
The company manufactures three million doses of the rabies vaccine in the country at its facility at Ahmedabad.
With this approval, it has become the first domestic pharma firm to receive the WHO accredition for rabies vaccine.
The vaccine, currently, is exported to countries in South Asia and Africa.
In the domestic market, the drug is marketed under the brand name Vaxirab.
On the Bombay Stock Exchange, the company's shares were trading at Rs 285, down 0.3 per cent at IST 1309.
